PA
CNST

Perceptive Advisors’s Constellation Pharmaceuticals, Inc. CNST Stock Holding History

Perceptive Advisors’s Portfolio CNST Stock Details CNST Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2020
Q1 		– Sell
-6,000
Closed -$283K – 138
2019
Q4 		$283K Buy
+6,000
New +$173K 0.01% 109

Other funds holding CNST

PS
Peter Svennilson $1.23B AUM 301.34% 1-Year Est. Return
VA
VR Adviser New York $2.68B AUM 422.73% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
BCLSI
Bain Capital Life Sciences Investors Boston, Massachusetts $1.11B AUM 171.34% 1-Year Est. Return
CAM
Cormorant Asset Management Boston, Massachusetts $1.99B AUM 737.95% 1-Year Est. Return
GPP
Great Point Partners Greenwich, Connecticut $435M AUM 318.81% 1-Year Est. Return
TG
TRV GP Boston, Massachusetts $18.9M AUM 541.67% 1-Year Est. Return
Point72 Asset Management
Point72 Asset Management Stamford, Connecticut $78.1B AUM 55.25% 1-Year Est. Return
ROTUOC
Regents of the University of California Oakland, California $3.01B AUM 11.91% 1-Year Est. Return

Perceptive Advisors's CNST Position: Q1 2020 in Review

Perceptive Advisors sold out of Constellation Pharmaceuticals, Inc. (CNST) in Q1 2020, closing a stake of 6,000 shares — an estimated $283K sold.

Perceptive Advisors first reported a position in CNST in Q4 2019 and held it in 1 quarter. The position peaked at $283K in Q4 2019. 99 funds tracked by Wall St. Rank hold CNST as of Q1 2020.

  • Perceptive Advisors reported no remaining Constellation Pharmaceuticals, Inc. position as of Q1 2020 after selling out during the quarter.
  • Perceptive Advisors sold 6,000 Constellation Pharmaceuticals, Inc. shares in Q1 2020, an estimated $283K.
  • Perceptive Advisors first reported a position in Constellation Pharmaceuticals, Inc. in Q4 2019 and held it in 1 quarter.
  • Perceptive Advisors's Constellation Pharmaceuticals, Inc. position peaked at $283K in Q4 2019.
  • 99 funds tracked by Wall St. Rank held Constellation Pharmaceuticals, Inc. as of Q1 2020.

Based on Perceptive Advisors's 13F filing for Q1 2020, filed 15 May 2020.